SG11201708602XA - Biologically cleavable tetrapeptide linking agents - Google Patents
Biologically cleavable tetrapeptide linking agentsInfo
- Publication number
- SG11201708602XA SG11201708602XA SG11201708602XA SG11201708602XA SG11201708602XA SG 11201708602X A SG11201708602X A SG 11201708602XA SG 11201708602X A SG11201708602X A SG 11201708602XA SG 11201708602X A SG11201708602X A SG 11201708602XA SG 11201708602X A SG11201708602X A SG 11201708602XA
- Authority
- SG
- Singapore
- Prior art keywords
- linking agents
- biologically cleavable
- cleavable tetrapeptide
- tetrapeptide linking
- biologically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168244P | 2015-05-29 | 2015-05-29 | |
| US201562235833P | 2015-10-01 | 2015-10-01 | |
| PCT/US2016/034517 WO2016196243A1 (en) | 2015-05-29 | 2016-05-27 | Biologically cleavable tetrapeptide linking agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708602XA true SG11201708602XA (en) | 2017-12-28 |
Family
ID=57398322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708602XA SG11201708602XA (en) | 2015-05-29 | 2016-05-27 | Biologically cleavable tetrapeptide linking agents |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10005815B2 (en) |
| EP (1) | EP3302516B1 (en) |
| JP (1) | JP6966427B2 (en) |
| KR (1) | KR102633963B1 (en) |
| CN (1) | CN107614002B (en) |
| AU (1) | AU2016270597B2 (en) |
| BR (1) | BR112017025719A2 (en) |
| CA (1) | CA2984499A1 (en) |
| EA (1) | EA036949B1 (en) |
| IL (1) | IL255999A (en) |
| MX (1) | MX2017014638A (en) |
| SG (1) | SG11201708602XA (en) |
| TW (1) | TWI732761B (en) |
| WO (1) | WO2016196243A1 (en) |
| ZA (1) | ZA201707149B (en) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
| GB9903087D0 (en) | 1999-02-12 | 1999-03-31 | Glaxo Group Ltd | Process |
| US7402556B2 (en) * | 2000-08-24 | 2008-07-22 | Medarex, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2008022309A2 (en) | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
| ES2647927T3 (en) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Auriestatin drug linker conjugates |
| US20100227920A1 (en) | 2008-09-29 | 2010-09-09 | The Regents Of The University Of California | Aldehyde dehydrogenase inhibitors as novel depigmenting agents |
| CA3151965A1 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| EP2382993A1 (en) * | 2010-04-19 | 2011-11-02 | KTB Tumorforschungsgesellschaft mbH | Combination of drugs with protein-binding prodrugs |
| CA2822161C (en) | 2010-12-29 | 2018-05-29 | Philipp Hadwiger | Small molecule conjugates for intracellular delivery of nucleic acids |
| EP2694530B1 (en) * | 2011-04-05 | 2018-02-14 | Curara AB | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment |
| CN103945870B (en) * | 2011-09-07 | 2016-10-12 | 普罗林科斯有限责任公司 | Biodegradable cross-linked hydrogel |
| US9732161B2 (en) * | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| WO2014052650A2 (en) * | 2012-09-26 | 2014-04-03 | Massachusetts Institute Of Technology | Modification of peptides via snar reactions of thiols with fluorinated aromatics |
| US9999680B2 (en) * | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
| WO2014200910A2 (en) * | 2013-06-10 | 2014-12-18 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2015021092A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| WO2015038426A1 (en) * | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
-
2016
- 2016-05-27 SG SG11201708602XA patent/SG11201708602XA/en unknown
- 2016-05-27 TW TW105116747A patent/TWI732761B/en active
- 2016-05-27 BR BR112017025719A patent/BR112017025719A2/en not_active Application Discontinuation
- 2016-05-27 WO PCT/US2016/034517 patent/WO2016196243A1/en active Application Filing
- 2016-05-27 KR KR1020177036710A patent/KR102633963B1/en active IP Right Grant
- 2016-05-27 AU AU2016270597A patent/AU2016270597B2/en active Active
- 2016-05-27 CA CA2984499A patent/CA2984499A1/en active Pending
- 2016-05-27 MX MX2017014638A patent/MX2017014638A/en unknown
- 2016-05-27 EP EP16804090.5A patent/EP3302516B1/en active Active
- 2016-05-27 CN CN201680031097.XA patent/CN107614002B/en active Active
- 2016-05-27 US US15/166,323 patent/US10005815B2/en active Active
- 2016-05-27 EA EA201792101A patent/EA036949B1/en not_active IP Right Cessation
- 2016-05-27 JP JP2018513741A patent/JP6966427B2/en active Active
-
2017
- 2017-10-20 ZA ZA2017/07149A patent/ZA201707149B/en unknown
- 2017-11-28 IL IL255999A patent/IL255999A/en unknown
-
2018
- 2018-05-25 US US15/990,415 patent/US20180258138A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017014638A (en) | 2018-01-23 |
| JP2018517769A (en) | 2018-07-05 |
| JP6966427B2 (en) | 2021-11-17 |
| US10005815B2 (en) | 2018-06-26 |
| US20160347793A1 (en) | 2016-12-01 |
| BR112017025719A2 (en) | 2018-08-07 |
| CA2984499A1 (en) | 2016-12-08 |
| CN107614002B (en) | 2022-01-04 |
| AU2016270597A1 (en) | 2017-11-09 |
| EP3302516A4 (en) | 2019-07-31 |
| EP3302516B1 (en) | 2020-12-30 |
| ZA201707149B (en) | 2019-02-27 |
| KR102633963B1 (en) | 2024-02-05 |
| US20180258138A1 (en) | 2018-09-13 |
| KR20180010235A (en) | 2018-01-30 |
| EA036949B1 (en) | 2021-01-19 |
| WO2016196243A1 (en) | 2016-12-08 |
| IL255999A (en) | 2018-01-31 |
| EA201792101A1 (en) | 2018-06-29 |
| TW201716426A (en) | 2017-05-16 |
| CN107614002A (en) | 2018-01-19 |
| TWI732761B (en) | 2021-07-11 |
| EP3302516A1 (en) | 2018-04-11 |
| AU2016270597B2 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201801556D0 (en) | Gearsets | |
| ZAA201800997S (en) | Neckwear | |
| ZAA201800910S (en) | Neckwear | |
| FI3753929T3 (en) | Dimeric contrast agents | |
| GB201714115D0 (en) | Cytotoxic agents | |
| IL265680B (en) | Dimeric contrast agents | |
| GB2566519B (en) | Theatre construction | |
| HK1257745A1 (en) | Peptide composition | |
| FI3554474T3 (en) | Micafungin compositions | |
| GB201713700D0 (en) | Peptide conjugates | |
| GB201612150D0 (en) | Modified peptide | |
| IL255999A (en) | Biologically cleavable tetrapeptide linking agents | |
| ZA201706866B (en) | Water-based disinfectant | |
| GB201709689D0 (en) | Flexible construction pillar | |
| HU1700092V0 (en) | Composter | |
| GB2593602B (en) | Theatre construction | |
| GB2593601B (en) | Theatre construction | |
| GB2583810B (en) | Theatre construction | |
| GB2583809B (en) | Theatre construction | |
| GB2583808B (en) | Theatre construction | |
| GB201720484D0 (en) | Patent X | |
| IL252767A0 (en) | Modular construction | |
| GB201702182D0 (en) | Gearsets | |
| GB201701683D0 (en) | Gearsets | |
| HUE052800T2 (en) | Contrast agents |